Source comparison
Selank Amidate Peptide vs Semax vs Noopept: Research Compound Comparison
Selank Amidate GABA-A receptor upregulation, enkephalin pathway modulation 20–30 minutes (plasma) 300–600 mcg intranasal or SC Anxiolytic without sedation or tolerance development Best-suited for anxiety models and stress-response research where benzodiazepine
This comparison does not assign a generated winner or score.
- Selank Amidate
- GABA-A receptor upregulation, enkephalin pathway modulation
- 20–30 minutes (plasma)
- 300–600 mcg intranasal or SC
- Anxiolytic without sedation or tolerance development
- Best-suited for anxiety models and stress-response research where benzodiazepine tolerance is a confound
- Semax
- BDNF upregulation, ACTH(4-10) analog
- 10–15 minutes (plasma)
- 600–1200 mcg intranasal
- Cognitive enhancement via neurotrophic signaling, no anxiolytic profile
- Preferred for memory consolidation and neuroprotection studies with no mood component
- Noopept
- AMPA receptor potentiation, NGF/BDNF elevation
- 25–40 minutes (oral)
- 10–30 mg oral
- Rapid-onset nootropic with racetam-like cognitive effects but distinct structure
- Most widely studied in Western labs; stronger acute cognitive effects but lacks Selank's anxiolytic component
- This comparison clarifies that Selank Amidate peptide occupies a unique research niche: it is the only peptide in this class demonstrating both anxiolytic and nootropic effects without GABAergic sedation or dopaminergic stimulation.